XRCC4 rs28360071 intronic variant is associated with increased risk for infant acute lymphoblastic leukemia with KMT2A rearrangements.


Journal

Genetics and molecular biology
ISSN: 1415-4757
Titre abrégé: Genet Mol Biol
Pays: Brazil
ID NLM: 100883590

Informations de publication

Date de publication:
2020
Historique:
received: 26 05 2020
accepted: 20 10 2020
entrez: 3 12 2020
pubmed: 4 12 2020
medline: 4 12 2020
Statut: epublish

Résumé

Early age acute leukemia (EAL) shows a high frequency of KMT2A-rearrangements (KMT2A-r). Previous investigations highlighted double-strand breaks arising from maternal exposure to xenobiotics during pregnancy as a risk factor for EAL and KMT2A-r. In this case-control study, we investigated the relationship between EAL and genetic variants of the nonhomologous end-joining (XRCC6 rs5751129, XRCC4 rs6869366 and rs28360071), since they might affect DNA repair capacity, leading to KMT2A-r and leukemogenesis. Samples from 577 individuals (acute lymphoblastic leukemia-ALL, n=164; acute myeloid leukemia-AML, n=113; controls, n=300) were genotyped. No significant association was found for rs5751129 and rs6869366, whereas rs28360071 was associated with an increased risk for ALL with KMT2A-r (IIxID: OR - Odds ratio 2.23, CI 1.17-4.25, p=0.014). Bone marrow samples from ALL patients showed a higher expression of XRCC4 compared to AML patients (p=0.025). Human Splicing Finder 3.1 predicted that the deleted allele of rs28360071 is potentially associated with the activation of a 5' cryptic splice site in intron 3 of XRCC4. The sequencing of cDNA did not show any differences on the splicing process for the rs28360071 genotypes. Our results suggest that the deleted allele for rs28360071 increases the risk for ALL with KMT2A-r, but not by modifying the XRCC4 expression levels or its structure.

Identifiants

pubmed: 33270074
pii: S1415-47572020000600111
doi: 10.1590/1678-4685-GMB-2020-0160
pmc: PMC7734917
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e20200160

Références

Leukemia. 2007 Sep;21(9):2061-4
pubmed: 17495966
Medicine (Baltimore). 2015 Jan;94(1):e283
pubmed: 25569644
Biochem Soc Trans. 2010 Dec;38(6):1615-20
pubmed: 21118136
Cancer Res. 2001 Mar 15;61(6):2542-6
pubmed: 11289128
Anticancer Res. 2010 Feb;30(2):529-33
pubmed: 20332465
PLoS One. 2015 May 18;10(5):e0127308
pubmed: 25992585
Nucleic Acids Res. 1998 Dec 1;26(23):5333-42
pubmed: 9826756
Nat Rev Genet. 2007 Oct;8(10):749-61
pubmed: 17726481
Environ Health Perspect. 1996 Dec;104 Suppl 6:1265-9
pubmed: 9118903
Cancer Biomark. 2012-2013;12(1):37-47
pubmed: 23321468
Nat Rev Cancer. 2003 Sep;3(9):639-49
pubmed: 12951583
J Biol Chem. 2008 Jan 4;283(1):1-5
pubmed: 17999957
Nat Struct Mol Biol. 2010 Apr;17(4):410-6
pubmed: 20208544
Anticancer Res. 2013 Feb;33(2):529-35
pubmed: 23393345
Blood. 2012 Oct 18;120(16):3187-205
pubmed: 22879540
Biosci Rep. 2019 Jan 15;39(1):
pubmed: 30429230
Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2336-41
pubmed: 17164354
Br J Biomed Sci. 2020 Jan;77(1):7-12
pubmed: 31250713
Haematologica. 2009 Jul;94(7):984-93
pubmed: 19535349
Med Pediatr Oncol. 2001 May;36(5):525-35
pubmed: 11340607
Curr Hematol Malig Rep. 2009 Jul;4(3):167-74
pubmed: 20425430
Cancer Causes Control. 2011 Dec;22(12):1721-30
pubmed: 21987080
Leuk Res. 2015 Feb;39(2):242-7
pubmed: 25510485
Pediatr Blood Cancer. 2006 Oct 15;47(5):549-54
pubmed: 16261608
Nucleic Acids Res. 2007;35(13):4250-63
pubmed: 17576681
Mol Biol Rep. 2014 Nov;41(11):7463-70
pubmed: 25096509
Neurosci Lett. 2011 Jul 1;498(1):67-71
pubmed: 21575681
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Br J Haematol. 2013 Apr;161(2):224-36
pubmed: 23432364
Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):177-82
pubmed: 12509516
Anticancer Res. 2013 Dec;33(12):5395-9
pubmed: 24324074
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Arch Med Res. 2016 Nov;47(8):593-606
pubmed: 28476187
Mol Vis. 2007 Aug 15;13:1436-40
pubmed: 17768380
Anticancer Res. 2012 Sep;32(9):3855-60
pubmed: 22993329
Annu Rev Genet. 2013;47:433-55
pubmed: 24050180

Auteurs

Orlando Louzada-Neto (O)

Universidade do Estado do Rio de Janeiro, Departamento de Bioquímica, Laboratório de Toxicologia e Biologia Molecular, Rio de Janeiro, RJ, Brazil.

Bruno A Lopes (BA)

Centro de Pesquisas, Instituto Nacional do Câncer, Programa de Hematologia-Oncologia Pediátrica, Rio de Janeiro, RJ, Brazil.

Gisele D Brisson (GD)

Centro de Pesquisas, Instituto Nacional do Câncer, Programa de Hematologia-Oncologia Pediátrica, Rio de Janeiro, RJ, Brazil.

Francianne G Andrade (FG)

Centro de Pesquisas, Instituto Nacional do Câncer, Programa de Hematologia-Oncologia Pediátrica, Rio de Janeiro, RJ, Brazil.

Ingrid S Cezar (IS)

Centro de Pesquisas, Instituto Nacional do Câncer, Programa de Hematologia-Oncologia Pediátrica, Rio de Janeiro, RJ, Brazil.

Cíntia B Santos-Rebouças (CB)

Universidade do Estado do Rio de Janeiro, Departamento de Genética, Rio de Janeiro, RJ, Brazil.

Rodolpho M Albano (RM)

Universidade do Estado do Rio de Janeiro, Departamento de Bioquímica, Laboratório de Toxicologia e Biologia Molecular, Rio de Janeiro, RJ, Brazil.

Maria S Pombo-de-Oliveira (MS)

Centro de Pesquisas, Instituto Nacional do Câncer, Programa de Hematologia-Oncologia Pediátrica, Rio de Janeiro, RJ, Brazil.

Ana Rossini (A)

Universidade do Estado do Rio de Janeiro, Departamento de Bioquímica, Laboratório de Toxicologia e Biologia Molecular, Rio de Janeiro, RJ, Brazil.

Classifications MeSH